Cannabis Market in Colombia

Colombia has emerged as one of the most interesting cannabis cultivation markets globally, leveraging its ideal equatorial growing conditions, low labor costs, and established agricultural export infrastructure. The country legalized medical and scientific cannabis in 2015 through Law 1787 and subsequent Decree 613 of 2017, which created a licensing framework for cultivation, manufacturing, and export. Colombia's government explicitly positioned the country as a low-cost cannabis production hub that could serve growing international demand, particularly in Europe and North America.

The Colombian cannabis industry benefits from natural advantages that no other major market can match. Twelve hours of consistent sunlight year-round, multiple harvest cycles, favorable altitude and climate conditions in regions like Cauca and Antioquia, and labor costs a fraction of those in North America or Europe give Colombian producers a significant cost-of-production advantage. Industry estimates suggest Colombian outdoor cultivation costs can be as low as $0.05-0.10 per gram, compared to $1-3+ per gram in indoor facilities in North America. This cost structure makes Colombia particularly attractive for producing CBD extracts, oils, and other processed products where cultivation cost is a major component.

However, the Colombian cannabis industry has faced significant challenges in translating these natural advantages into commercial success. Regulatory processes for obtaining export licenses have been slower and more complex than anticipated. International market access requires not only Colombian regulatory approval but also import authorization from destination countries, creating a double barrier. Additionally, the quality standards required for pharmaceutical-grade cannabis — particularly EU-GMP certification — require significant capital investment that many Colombian startups have struggled to secure. The gap between Colombia's cultivation potential and its commercial output has been wider than early optimists projected.

Several companies have attempted to build the Colombian cannabis export model, with mixed results. Blueberries Medical Corp, Clever Leaves (now part of Cleana), PharmaCielo, and Flora Growth have been among the publicly traded companies with Colombian operations. Many of these companies have pivoted their strategies over time, shifting from pure cultivation plays to more integrated models that include processing, branding, and direct market access. The success of the Colombian cannabis model ultimately depends on whether international medical markets continue to grow and whether the cost advantage can overcome the regulatory complexity of cross-border cannabis trade.